Theolytics, a biotech company aimed at producing curative cancer therapies, has named Carsten Reinhardt MD PhD as its new director, it was reported on Monday.
Dr Reinhardt is an oncology and biotech expert, with experience in translational development and early and late-stage clinical trial design, progressing multiple biological compounds from early preclinical development through first-in-man studies towards approvals in the US and Europe.
Dr Reinhardt is serving as the chief development officer and managing director of Immatics Biotechnologies GmbH. Prior to joining Immatics, he has served Micromet Inc as CMO and on the management board. He has also held the position of head of Clinical Development at Germany's Fresenius Biotech. He has also served at Hoffmann-La Roche.
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Enable Biosciences names new chief financial officer
Cadenza Bio names new director
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation